UC DDC Seed Grant RFA Cycle 2 Four seed grants, $50K – 100K direct costs/one year, earliest funding start date mid-November. Deadline for non-confidential Letters of Intent: August 31, 2022 (11:59 pm) The UC DDC aims to assist faculty researchers across the University of California advance the creation of drugs that address important unmet medical needs. In partnership with industrial sponsors, we provide seed funding that enables faculty members to advance promising drug discovery/development projects, with the goal of generating data that will enable them to secure federal, philanthropic, or commercial support and thus further advance their projects. Our industrial partner for this request for applications is Astellas Pharma, Inc. Areas of interest in Oncology: • Modulation of tumor microenvironment • Highly tumor-specific antigens/markers • Novel targeted protein degrader platforms • Engineered antibodies and other biologics For more information and to access the LOI form: https://uci.infoready4.com/#competitionDetail/1875388 More Info LOI due: Aug 31, 2022 - 8:59:PM Learn More Agency University of California Drug Discovery Consortium (UC DDC) Type Other Disciplines Basic Science Translational Research Early Career
UC DDC Seed Grant RFA Cycle 2 Four seed grants, $50K – 100K direct costs/one year, earliest funding start date mid-November. Deadline for non-confidential Letters of Intent: August 31, 2022 (11:59 pm) The UC DDC aims to assist faculty researchers across the University of California advance the creation of drugs that address important unmet medical needs. In partnership with industrial sponsors, we provide seed funding that enables faculty members to advance promising drug discovery/development projects, with the goal of generating data that will enable them to secure federal, philanthropic, or commercial support and thus further advance their projects. Our industrial partner for this request for applications is Astellas Pharma, Inc. Areas of interest in Oncology: • Modulation of tumor microenvironment • Highly tumor-specific antigens/markers • Novel targeted protein degrader platforms • Engineered antibodies and other biologics For more information and to access the LOI form: https://uci.infoready4.com/#competitionDetail/1875388 More Info LOI due: Aug 31, 2022 - 8:59:PM Learn More Agency University of California Drug Discovery Consortium (UC DDC) Type Other Disciplines Basic Science Translational Research Early Career